Malignant Glioma of Brain Clinical Trial
Official title:
A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)). During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will be started on the day of TMZ initiation and continued for a total of 21 days.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
| Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
| Completed |
NCT03355794 -
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
|
Phase 1 | |
| Recruiting |
NCT04937244 -
Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
|
Phase 4 | |
| Recruiting |
NCT03423992 -
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
|
Phase 1 | |
| Not yet recruiting |
NCT04482933 -
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT06417281 -
Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）
|
Phase 3 | |
| Withdrawn |
NCT03176160 -
LITT Palliative Treatment for Patients With Malignant Gliomas
|
||
| Recruiting |
NCT02839954 -
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03152318 -
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
|
Phase 1 | |
| Completed |
NCT00870181 -
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
|
Phase 2 | |
| Completed |
NCT01550523 -
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
|
Phase 1 | |
| Terminated |
NCT01017653 -
Panitumumab and Irinotecan for Malignant Gliomas
|
Phase 2 |